reason report
weigh pt
bottom line disappoint result
guid disappoint concern on-going
potenti escal issu pharmedium believ
on-going delay difficult win back lost
custom though core busi seem perform
well navig sever headwind includ on-going client
platform lash pharmedium continu invest
busi price trend describ consist
guidanc encourag gener deflat seem
stabil brand inflat trend fairli well despit
increas scrutini washington overal come away
quarter disappoint consist lack execut pt
reduc estim
reduc follow guid
busi appear perform well follow
disappoint quarter believ import note
core busi appear perform well though revenu
disappoint rel model distribut revenu y/
adj oper incom segment beat estim adj
opex increas y/i due brazil busi hd smith
manag claim ex-pharmedium brazil busi
adj oper incom would mid-singl digit y/i
quarter vs y/i
price trend line prior guidanc continu
stabil gener trend bode well distribut group
call manag gave detail price trend data believ
posit intend help underscor manag messag
ex-pharmedium pharma segment perform well brand
price reportedli end year
middl guid rang disclos
brand buy-sid compens cover fee-for-
servic contract believ affirm continu brand price
increas bode well distributor especi light scrutini
washington point manag explain price
increas would surpris current environ
gener deflat describ slightli wors
high-end previous guid rang
 manag continu describ stabl environ
explain percentag improv deflat
meaning light improv gener deflat trend
gener manufactur portfolio ration manag express
optimist view futur
net debt total capit
ep
estimate lt ep growth base
compani inform leerink partner llc research
revenu present billion dollar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
pharmedium remain problem neg surpris
morn disclos memphi pharmedium plant
still commenc commerci oper doj
involv along fda last quarter manag explain
expect would bring memphi plant back line
intend start commerci shipment august appar
never happen addit delay still lack clariti
doj involv concern manag
implement enhanc process three facil
includ enhanc qualiti procedur test may
reduc volum ship manag character impact
on-going headwind impact oper incom growth
pharma distribut segment manag previous size
headwind oper incom estim
mid-singl digit growth enterpris impli oper
incom pharmedium manag
guid plant restart oper receiv
fda feedback given delay work pharmedium
suggest may difficult win back lost custom link come
away disappoint ceo steve colli said call
hard gaug exactli market respond
guidanc disappoint pharmedium weigh guidanc
introduc disappoint rel prior estim adj ep
guid rang y/i behind prior
leerink/consensu manag provid
quarterli guidanc guid y/i due tough
pharmedium comp expect stronger earn
guid includ consolid profarma specialti
jv brazil lap increment invest made januari
boost y/i result embed guidanc
manag character three scenario pharmedium
led pharma distribut oper incom guidanc
low-singl mid-singl digit percent growth togeth
divis guidanc high-singl digit percent oper incom growth
manag expect overal oper incom low-singl
mid-singl digit percent y/i guidanc assum brand inflat
mid-singl digit y/i gener deflat consist
price environ experienc toward tail-end
y/i go forward manag longer provid guidanc
gener deflat due trend stabil manag
express optim normal deflat adj opex
grown due hd smith acquisit pharmedium consolid
brazil busi guid almost certainli
high-end mid-singl digit y/i growth howev encourag
hear hd smith integr sound progress well
manag guid meet run-rat accret target
time captur synergi move
outlook disappoint encourag
guid ramp pharmedium abil drive potenti
tweak estim pt though core
busi continu perform well price trend appear
benefici group concern on-going potenti
escal issu pharmedium guid disappoint
estim reduc guid quarter
pt declin
one pharmaceut distributor estim compani
captur pharmaceut distribut market term revenu
primari differenti distributor compani
focu specialti drug firm relationship estim
compani revenu deriv amerisourcebergen specialti group half
total revenu come oncology-rel busi come
drug compani non-specialti drug servic believ compani concentr
oncology-rel drug posit mani larg pend launch market
compani seem intens focu keep cost lean drive oper
margin expans watch measur everi basi point oper margin expans
quarterwhich view posit furthermor manag tend return signific
portion compani free cash flow back sharehold via common stock repurchas
dividend final abc relationship walgreen signific posit view sinc
walgreen own portion sinc walgreen use primari
distributor stand benefit wba growth market includ increment
volum result wba/ transact well increment volum
narrow network deal recent ink includ deal esrx/tricar optum
prime envis headwind exist includ competit sell-sid
environ on-going risk brand gener inflat rate presid trump potenti
polici around brand price unclear though believ ultim work industri
despit risk believ concern current reflect share
price increment revenu off-set mani headwind view given
abc grow market share seemingli decent brand inflat rate purchas power
wbad growth specialti market rate share outperform
share trade ep estim behind
ntm price-to-earnings histor averag rel ep trade
trade view deserv premium
group mainli abc relationship transact believ
new client win posit renew comp eas higher oper cost
allevi trend gener deflat stabil next month
expect share trade ep would put stock
competit intens amerisourcebergen compet two larg drug distributor
competit among intens could lead
either posit neg earn revis furthermor chain independ
consolid usual one distributor retain contract exampl walgreen
acquisit duan read acquisit long unfavor impact
result larg billion dollar piec busi often
chang hand occurr happen past may happen
futur competit could also lead price eros medco health solut part
esrx repres revenu pre-wag top ten custom repres
revenu pre-wag custom lost could materi advers
impact earn share price custom face financi hardship
abil collect receiv could becom challeng insolv
supplier could also result advers impact financi result stock
price economi impact earn result
brand-nam manufactur buy-sid contract fee-for-servic ff arrang
inflat deflat brand-nam drug usual less impact earn
rel contract ff howev sinc price receiv custom often
inflation-bas compon earn could unfavor impact addit economi
weak fewer peopl actual buy prescript drug due concern discretionari
spend lack health insur compani margin could come pressur
govern regul could advers impact compani
pharmaceut drug distribut industri highli regul state feder agenc
includ fda variou state board law pass
may pass futur intent increas safeti may like result
higher cost exampl radio frequenc identif devic may
prove costli track trace chain custodi technolog
also requir hold valid state-level licens meet variou secur oper
standard failur compli feder state local law could advers impact
compani earn
chang reimburs rate could impact earn effect januari
deficit reduct act dra chang feder upper limit
lowest publish price gener averag manufactur price
health reform set less medicaid
improv patient provid act mippa delay adopt
make public least delay implement set
becom public reimburs compani retail custom come
pressur could advers impact firm sell-sid margin addit
reimburs rate chang awp awp roll back could
unfavor impact earn declin asp reimburs
medicar certain specialti drug could also advers impact result
compani revenu growth rate certain drug use oncolog
come pressur expand warn product safeti label nation coverag
decis could advers impact compani revenu growth rate
reform drug reimburs chang canada could also advers impact
compani earn power
chang due health reform could advers impact compani product
servic highli complex pervas throughout entir healthcar system
extens array reimburs mechan player within industri
includ manag care medicar medicaid pbm supplier materi chang
entiti health reform could impact margin
consolid competitor supplier custom purchas group could
advers impact compani earn
litig alway risk compani subject signific number healthcar law
includ fals claim act whistl blower act law relat sale purchas
pharmaceut product exampl offer remuner provid use certain drug
may illeg case
oper risk compani make acquisit risk integr
could caus cost rise oper issu occur addit compani embark
cost save program well streamlin process could result oper
issu data lost compani new implement program face
challeng could advers impact compani earn share price
implement compani enterpris resourc plan erp system could also
advers impact earn oper
incom statement model fiscal year end septemb mm
good sold
distribut sell administr
total revenu
total revenu
impair intang
amort intang
total revenu
total revenu
weight average number share
employe sever litig
